• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

HYDERABAD: Aurobindo Pharma Ltd (APL) has announced that it has received the tentative approval of the United States Food and Drug Administration (USFDA) for its anti-AIDS drug Lamivudine oral solution 10mg/ml.

The USFDA approval qualifies APL under the President's Emergency Plan for AIDS Relief (PEPFAR) programme, the company said in a press release here on Monday. Aurobindo Pharma already has seven product approvals under the PEPFAR programme. According to the company, Lamivudine oral solution 10mg/ml is the first generic version approval of GlaxoSmithKline's oral solution `Epivir'. Lamivudine, an antiviral drug, is used to treat infections due to hepatitis-B and human immunodeficiency virus (HIV).

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
L&T giant platform sets sail for Abu Dhabi from Hazira

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line